Your session is about to expire
← Back to Search
Pembrolizumab + Sunitinib for Thymic Cancer
Study Summary
This trial is studying pembrolizumab and sunitinib malate to treat thymic cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am currently being treated for an infection.I have not had a clot in my arteries in the last 6 months.I have a heart rhythm problem that is moderate to severe.I can swallow and keep down pills.I have a recent or stored tumor tissue sample available.I am fully active or restricted in physically strenuous activity but can do light work.My blood pressure is under control.I am not currently in a study or haven't used a study device in the last 4 weeks.I have been treated with sunitinib or pembrolizumab before.My kidney function, measured by creatinine or GFR, is within the normal range.I am of childbearing age and my pregnancy test is negative.I have an active case of tuberculosis.I have not needed treatment for an autoimmune disease in the last 2 years.My thymic carcinoma is advanced and cannot be cured with treatment.My cancer has worsened after receiving platinum-based chemotherapy.I am willing to undergo a biopsy for my treatment.I am using reliable birth control methods.I have an immune system disorder or have taken steroids in the last week.I am a man who can father a child and will use birth control.I have been treated with drugs targeting PD-1, PD-L1, or PD-L2.I have a serious wound or fracture that is not healing.I have not had chemotherapy, targeted therapy, or radiation in the last 2 weeks.I have not received a live vaccine in the last 30 days.My cancer has spread to my brain or its coverings.I am using or might need strong medication that affects liver enzymes.I am not allergic to pembrolizumab or sunitinib.I have had severe bleeding in the last 4 weeks.I have another cancer that is getting worse or needs treatment.I have a history of HIV or active hepatitis B or C.
- Group 1: Treatment (pembrolizumab, sunitinib malate)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is enrollment in this research endeavor currently open?
"Affirmative. Clinicaltrials.gov verifies that the trial, which was first launched on June 19th 2018, is presently in need of participants. In total, 40 patients will be enrolled from 3 clinical centres."
What is the recruitment rate of this medical trial?
"Forty potential candidates that meet the predefined criteria must join this research initiative. Participants can register at one of two medical centres; Indiana University in Indianapolis, IN and Ohio State University Comprehensive Cancer Center in Columbus, OH."
Has Pembrolizumab gained authorization from the Food and Drug Administration?
"Pembrolizumab's safety is rated as a 2 due to limited evidence suggesting its efficacy, though there has been data collected supporting the drug's safety."
To what diseases is Pembrolizumab typically prescribed?
"Pembrolizumab is often prescribed for cancerous neoplasms, and can also be utilized to address unresectable melanoma, microsatellite instability high, as well as cases with a heightened risk of relapse."
Have any past experiments involved the use of Pembrolizumab?
"Pembrolizumab was investigated for the first time in 2006 at DuPage Medical Group - Joliet. Since then, 1041 studies have been completed and 988 are presently ongoing; many of them taking place in Indianapolis, Indiana."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger